Shionogi and Osaka Metropolitan University Form Strategic Alliance to Combat Infectious Diseases
Key Insights
Shionogi (search) and Osaka Metropolitan University have established a comprehensive collaboration agreement focused on infectious disease research, diagnostics development, and public health system strengthening.
The partnership will leverage Osaka Metropolitan University's broad academic expertise through OIRCID and Shionogi (search)'s pharmaceutical innovation capabilities to create an 'Osaka Model' for pandemic preparedness.
The collaboration encompasses education, research, public health system enhancement, and policy development, with specific focus on preventing and responding to future infectious disease crises.
In a significant move to strengthen infectious disease preparedness and response capabilities, Shionogi (search) & Co., Ltd. and Osaka Metropolitan University announced the signing of a comprehensive collaboration agreement on March 3, 2025. The partnership focuses on advancing information sharing, research technology, and human resource development in the field of infectious diseases (search).
Building on Existing Collaboration
The new agreement expands upon ongoing joint initiatives between the two organizations, including the development of next-generation diagnostic technologies for acute respiratory infections (search) and the establishment of a clinical research network. Both institutions leverage their strategic presence in Osaka Prefecture to maximize collaborative potential.
Comprehensive Partnership Framework
The collaboration encompasses six key initiatives:
- International education, research, and information dissemination
- Public health system reinforcement
- Crisis preparedness and response measures
- Policy recommendations for local government
- Academic and research personnel exchange
- Additional initiatives supporting agreement objectives
Innovative Research Infrastructure
Osaka Metropolitan University's recently established Osaka International Research Center for Infectious Diseases (search) (OIRCID), launched in February 2023, serves as a crucial component of this partnership. The center approaches infectious disease research from a macro-scientific perspective, complementing Shionogi (search)'s 60-year track record in infectious disease drug development.
Strategic Impact and Future Outlook
The partnership aims to establish an 'Osaka Model' through industry-government-academia collaboration, setting a new standard for infectious disease management. This model will focus on effective prevention, preparedness, and response measures for potential future pandemics.
Dr. Isao Teshirogi, CEO of Shionogi (search), and President Masahiro Tatsumisago of Osaka Metropolitan University will oversee the implementation of this comprehensive agreement, which is expected to significantly impact public health outcomes both locally and internationally.
Regional and Global Benefits
The collaboration leverages Osaka Metropolitan University's position as a knowledge hub, integrating expertise from 15 graduate schools with Shionogi (search)'s pharmaceutical innovation capabilities. This synergy aims to deliver tangible benefits to society while strengthening public health systems in Osaka Prefecture and beyond.